

Special Issue

Growth Factors and Lung Cancer

Message from the Guest Editor

Growth factor plays a pivotal role in lung cancer tumorigenesis by regulating multiple cellular processes such as cell proliferation, survival, invasion, and angiogenesis. Targeting a growth factor and its receptor has tremendous potential for the treatment of lung cancer. Growth factor is also crucial given that it involves intrinsic and acquired resistance to molecular targeted therapy and immunotherapy. One of the most extensively studied growth factors is vascular endothelial growth factor (VEGF), which promotes lung tumor growth and metastasis and confers resistance to various types of anti-cancer therapies by activating bypass pathways or modulating tumor immune microenvironments, and targeting VEGF has been shown to enhance the effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors or chemotherapy with/without immune checkpoint inhibitors in non-small-cell lung cancer. This Special Issue will highlight growth factors that affect lung tumorigenesis and therapeutic resistance, leading to a better understanding of the significance of growth factors as therapeutic targets and predictive/prognostic biomarkers in lung cancer.

Guest Editor

Dr. Noriaki Sunaga

Department of Respiratory Medicine, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi 371-8511, Japan

Deadline for manuscript submissions

closed (15 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/121358

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)